Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021; 397: 1375–86—In this Article, N Vora should not have been included in the SANAD II collaborators list. This correction has been made to the online version as of May 13, 2021.
. 2021 May 15;397(10287):1808. doi: 10.1016/S0140-6736(21)01011-4
Department of Error
© 2021 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
PMCID: PMC8140402 PMID: 33992147
